NRG1 and cancer: The results in this study showed HER3 activation upon HER2Mab treatment in both MCF7 (low HER2) and MCF7-HER2 (high HER2) cancer cells independent of the HER3 ligand NRG1, and HER3 activation is a result of HER3/EGFR dimerization.